Clinical Trials Browser

Phase 3 × pegfilgrastim × Breast × Clear all

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT00070564 2025-07-31

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Phase 3 Active not recruiting

3,294 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00433420 2024-05-08

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03252431 2023-07-03

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Phase 3 Completed

393 enrolled 20 charts

Breast Neoplasms, Neutropenia

NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Phase 3 Completed

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

NCT02643420 2022-03-02

ADVANCE

Phase 3 Completed

406 enrolled 19 charts

Breast Neoplasms, Neutropenia

NCT02953340 2022-03-02

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Phase 3 Completed

237 enrolled 18 charts

Breast Neoplasms, Neutropenia

NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Phase 3 Completed

BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

NCT00536081 2019-11-06

Various G-CSF Regimens to Prevent Infection During Chemotherapy

Phase 3 Completed

BreastClassical hematology

Breast Neoplasms, Febrile Neutropenia

NCT00301925 2018-08-08

TACT2

Phase 3 Unknown

Breast Neoplasms, Breast Neoplasms, Male

NCT03404752 2018-01-19

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

Phase 3 Unknown

Breast Neoplasms, Neutropenia

NCT03381417 2018-01-02

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Phase 3 Completed

Breast Cancer Female

NCT01516736 2017-08-30

PROTECT2

Phase 3 Completed

308 enrolled 19 charts

Breast Neoplasms, Neutropenia

NCT01735175 2017-08-07

PROTECT-1

Phase 3 Completed

316 enrolled 20 charts

Breast Neoplasms, Neutropenia

NCT01519700 2015-05-06

PIONEER

Phase 3 Completed

218 enrolled 15 charts

Breast Neoplasms, Neutropenia

NCT01985724 2014-05-14

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00516425 2013-08-07

Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00035594 2013-05-09

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Phase 3 Completed

Breast Neoplasms, Neutropenia

NCT00117910 2008-05-16

Treatment for Elderly Patients With High Risk Breast Cancer

Phase 3 Completed

Breast Neoplasms, Neutropenia

NCT00431080 2008-01-21

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Phase 3 Completed

Breast Neoplasms